CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo

Leena Chaudhuri, Nicole D. Vincelette, Brian D. Koh, Ryan M. Naylor, Karen S. Flatten, Kevin L. Peterson, Amanda McNally, Ivana Gojo, Judith E. Karp, Ruben A. Mesa, Lisa Sproat, James M. Bogenberger, Scott H Kaufmann, Raoul Tibes

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Novel combinations targeting new molecular vulnerabilities are needed to improve the outcome of patients with acute myeloid leukemia. We recently identified WEE1 kinase as a novel target in leukemias. To identify genes that are synthetically lethal with WEE1 inhibition, we performed a short interfering RNA screen directed against cell cycle and DNA repair genes during concurrent treatment with the WEE1 inhibitor MK1775. CHK1 and ATR, genes encoding two replication checkpoint kinases, were among the genes whose silencing enhanced the effects of WEE1 inhibition most, whereas CDK2 short interfering RNA antagonized MK1775 effects. Building on this observation, we examined the impact of combining MK1775 with selective small molecule inhibitors of CHK1, ATR and cyclin-dependent kinases. The CHK1 inhibitor MK8776 sensitized acute myeloid leukemia cell lines and primary leukemia specimens to MK1775 ex vivo, whereas smaller effects were observed with the MK1775/MK8776 combination in normal myeloid progenitors. The ATR inhibitor VE-821 likewise enhanced the antiproliferative effects of MK1775, whereas the cyclin-dependent kinase inhibitor roscovitine antagonized MK1775. Further studies showed that MK8776 enhanced MK1775-mediated activation of the ATR/CHK1 pathway in acute leukemia cell lines and ex vivo. These results indicate that combined cell cycle checkpoint interference with MK1775/MK8776 warrants further investigation as a potential treatment for acute myeloid leukemia.

Original languageEnglish (US)
Pages (from-to)688-696
Number of pages9
JournalHaematologica
Volume99
Issue number4
DOIs
StatePublished - 2014

Fingerprint

Acute Myeloid Leukemia
Leukemia
Therapeutics
Cyclin-Dependent Kinases
Small Interfering RNA
Phosphotransferases
Lethal Genes
MK 1775
Cell Line
Gene Silencing
Myeloid Cells
Cell Cycle Checkpoints
DNA Repair
Genes
Cell Cycle
MK-8776

ASJC Scopus subject areas

  • Hematology

Cite this

Chaudhuri, L., Vincelette, N. D., Koh, B. D., Naylor, R. M., Flatten, K. S., Peterson, K. L., ... Tibes, R. (2014). CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo. Haematologica, 99(4), 688-696. https://doi.org/10.3324/haematol.2013.093187

CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo. / Chaudhuri, Leena; Vincelette, Nicole D.; Koh, Brian D.; Naylor, Ryan M.; Flatten, Karen S.; Peterson, Kevin L.; McNally, Amanda; Gojo, Ivana; Karp, Judith E.; Mesa, Ruben A.; Sproat, Lisa; Bogenberger, James M.; Kaufmann, Scott H; Tibes, Raoul.

In: Haematologica, Vol. 99, No. 4, 2014, p. 688-696.

Research output: Contribution to journalArticle

Chaudhuri, L, Vincelette, ND, Koh, BD, Naylor, RM, Flatten, KS, Peterson, KL, McNally, A, Gojo, I, Karp, JE, Mesa, RA, Sproat, L, Bogenberger, JM, Kaufmann, SH & Tibes, R 2014, 'CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo', Haematologica, vol. 99, no. 4, pp. 688-696. https://doi.org/10.3324/haematol.2013.093187
Chaudhuri, Leena ; Vincelette, Nicole D. ; Koh, Brian D. ; Naylor, Ryan M. ; Flatten, Karen S. ; Peterson, Kevin L. ; McNally, Amanda ; Gojo, Ivana ; Karp, Judith E. ; Mesa, Ruben A. ; Sproat, Lisa ; Bogenberger, James M. ; Kaufmann, Scott H ; Tibes, Raoul. / CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo. In: Haematologica. 2014 ; Vol. 99, No. 4. pp. 688-696.
@article{ae04d0fb269f4f8f9243b00fa39a271c,
title = "CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo",
abstract = "Novel combinations targeting new molecular vulnerabilities are needed to improve the outcome of patients with acute myeloid leukemia. We recently identified WEE1 kinase as a novel target in leukemias. To identify genes that are synthetically lethal with WEE1 inhibition, we performed a short interfering RNA screen directed against cell cycle and DNA repair genes during concurrent treatment with the WEE1 inhibitor MK1775. CHK1 and ATR, genes encoding two replication checkpoint kinases, were among the genes whose silencing enhanced the effects of WEE1 inhibition most, whereas CDK2 short interfering RNA antagonized MK1775 effects. Building on this observation, we examined the impact of combining MK1775 with selective small molecule inhibitors of CHK1, ATR and cyclin-dependent kinases. The CHK1 inhibitor MK8776 sensitized acute myeloid leukemia cell lines and primary leukemia specimens to MK1775 ex vivo, whereas smaller effects were observed with the MK1775/MK8776 combination in normal myeloid progenitors. The ATR inhibitor VE-821 likewise enhanced the antiproliferative effects of MK1775, whereas the cyclin-dependent kinase inhibitor roscovitine antagonized MK1775. Further studies showed that MK8776 enhanced MK1775-mediated activation of the ATR/CHK1 pathway in acute leukemia cell lines and ex vivo. These results indicate that combined cell cycle checkpoint interference with MK1775/MK8776 warrants further investigation as a potential treatment for acute myeloid leukemia.",
author = "Leena Chaudhuri and Vincelette, {Nicole D.} and Koh, {Brian D.} and Naylor, {Ryan M.} and Flatten, {Karen S.} and Peterson, {Kevin L.} and Amanda McNally and Ivana Gojo and Karp, {Judith E.} and Mesa, {Ruben A.} and Lisa Sproat and Bogenberger, {James M.} and Kaufmann, {Scott H} and Raoul Tibes",
year = "2014",
doi = "10.3324/haematol.2013.093187",
language = "English (US)",
volume = "99",
pages = "688--696",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "4",

}

TY - JOUR

T1 - CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo

AU - Chaudhuri, Leena

AU - Vincelette, Nicole D.

AU - Koh, Brian D.

AU - Naylor, Ryan M.

AU - Flatten, Karen S.

AU - Peterson, Kevin L.

AU - McNally, Amanda

AU - Gojo, Ivana

AU - Karp, Judith E.

AU - Mesa, Ruben A.

AU - Sproat, Lisa

AU - Bogenberger, James M.

AU - Kaufmann, Scott H

AU - Tibes, Raoul

PY - 2014

Y1 - 2014

N2 - Novel combinations targeting new molecular vulnerabilities are needed to improve the outcome of patients with acute myeloid leukemia. We recently identified WEE1 kinase as a novel target in leukemias. To identify genes that are synthetically lethal with WEE1 inhibition, we performed a short interfering RNA screen directed against cell cycle and DNA repair genes during concurrent treatment with the WEE1 inhibitor MK1775. CHK1 and ATR, genes encoding two replication checkpoint kinases, were among the genes whose silencing enhanced the effects of WEE1 inhibition most, whereas CDK2 short interfering RNA antagonized MK1775 effects. Building on this observation, we examined the impact of combining MK1775 with selective small molecule inhibitors of CHK1, ATR and cyclin-dependent kinases. The CHK1 inhibitor MK8776 sensitized acute myeloid leukemia cell lines and primary leukemia specimens to MK1775 ex vivo, whereas smaller effects were observed with the MK1775/MK8776 combination in normal myeloid progenitors. The ATR inhibitor VE-821 likewise enhanced the antiproliferative effects of MK1775, whereas the cyclin-dependent kinase inhibitor roscovitine antagonized MK1775. Further studies showed that MK8776 enhanced MK1775-mediated activation of the ATR/CHK1 pathway in acute leukemia cell lines and ex vivo. These results indicate that combined cell cycle checkpoint interference with MK1775/MK8776 warrants further investigation as a potential treatment for acute myeloid leukemia.

AB - Novel combinations targeting new molecular vulnerabilities are needed to improve the outcome of patients with acute myeloid leukemia. We recently identified WEE1 kinase as a novel target in leukemias. To identify genes that are synthetically lethal with WEE1 inhibition, we performed a short interfering RNA screen directed against cell cycle and DNA repair genes during concurrent treatment with the WEE1 inhibitor MK1775. CHK1 and ATR, genes encoding two replication checkpoint kinases, were among the genes whose silencing enhanced the effects of WEE1 inhibition most, whereas CDK2 short interfering RNA antagonized MK1775 effects. Building on this observation, we examined the impact of combining MK1775 with selective small molecule inhibitors of CHK1, ATR and cyclin-dependent kinases. The CHK1 inhibitor MK8776 sensitized acute myeloid leukemia cell lines and primary leukemia specimens to MK1775 ex vivo, whereas smaller effects were observed with the MK1775/MK8776 combination in normal myeloid progenitors. The ATR inhibitor VE-821 likewise enhanced the antiproliferative effects of MK1775, whereas the cyclin-dependent kinase inhibitor roscovitine antagonized MK1775. Further studies showed that MK8776 enhanced MK1775-mediated activation of the ATR/CHK1 pathway in acute leukemia cell lines and ex vivo. These results indicate that combined cell cycle checkpoint interference with MK1775/MK8776 warrants further investigation as a potential treatment for acute myeloid leukemia.

UR - http://www.scopus.com/inward/record.url?scp=84897429295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897429295&partnerID=8YFLogxK

U2 - 10.3324/haematol.2013.093187

DO - 10.3324/haematol.2013.093187

M3 - Article

C2 - 24179152

AN - SCOPUS:84897429295

VL - 99

SP - 688

EP - 696

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 4

ER -